Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hillard Lazarus

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Haematologica|August 19, 2017
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databasesStaci D Arnold, Ruta Brazauskas, Naya He, et al.
Cancer|October 21, 2020
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United StatesSanghee Hong, Ruta Brazauskas, Kyle M Hebert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 1, 2019
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research StudyZachariah DeFilipp, Richard Ancheta, Ying Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 20, 2016
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaRobert F Cornell, Anita D'Souza, Adetola A Kassim, et al.
Blood|July 5, 2017
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, Marcelo C Pasquini, Michael Martens, et al.
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Blood Advances|September 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLKamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research ReportHaesook T Kim, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Leukemia Research|July 30, 2018
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myelomaTomas Radivoyevitch, Robert M Dean, Bronwen E Shaw, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Haematologica|August 19, 2017
Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databasesStaci D Arnold, Ruta Brazauskas, Naya He, et al.
Cancer|October 21, 2020
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United StatesSanghee Hong, Ruta Brazauskas, Kyle M Hebert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 1, 2019
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research StudyZachariah DeFilipp, Richard Ancheta, Ying Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 20, 2016
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaRobert F Cornell, Anita D'Souza, Adetola A Kassim, et al.
Blood|July 5, 2017
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, Marcelo C Pasquini, Michael Martens, et al.
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Blood Advances|September 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLKamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research ReportHaesook T Kim, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Leukemia Research|July 30, 2018
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myelomaTomas Radivoyevitch, Robert M Dean, Bronwen E Shaw, et al.
Pageof 5